CoChat

Early effects of roflumilast on insulin sensitivity in adults with prediabetes and overweight/obesity involve age-associated fat mass loss – results of an exploratory study

Open access

The DOI matches its Crossref record; 65 of the 65 references it cites were found in a registry or an index.

Abstract

Purpose: Roflumilast (Daliresp, Daxas) is a FDA-approved phosphodiesterase 4 (PDE4) inhibitor for the treatment of moderate-to-severe chronic obstructive pulmonary disease. In mice and in limited human studies, this oral medication can cause weight loss and improve insulin sensitivity. We set out to determine the mechanism of its effect on insulin sensitivity. Patients and methods: Eight adults with overweight/obesity and prediabetes received roflumilast for 6 weeks. Before and after roflumilast, subjects underwent tests of insulin sensitivity, mixed meal test, body composition, markers of inflammation, and mitochondria function. Dietary intake and physical activity were also assessed. Our primary outcome was the change in peripheral insulin sensitivity, as assessed by the hyper-insulinemic euglycemic clamp. Results: This study was underpowered for the primary outcome. Pre- and post-roflumilast mean peripheral insulin sensitivity were 48.7 and 70.0 mg/g fat free mass/minute, respectively, ( P -value=0.18), respectively. Among the mixed meal variables, roflumilast altered glucagon-like peptide 1 (GLP-1) hormone the most, although the average effect was not statistically significant ( P =0.18). Roflumilast induced a trend toward significance in 1) decreased energy intake (from 11,095 KJ to 8,4555 KJ, P =0.07), 2) decreased fat mass (from 34.53 to 32.97 kg, P =0.06), 3) decreased total and LDL cholesterol ( P =0.06 for both variables), and 4) increased plasma free fatty acids (from 0.40 to 0.50 mEq/L, P =0.09) The interval changes in adiposity and free fatty acid were significantly associated with the subject’s age ( P -value range=<0.001 to 0.02 for the correlations). Inflammatory and adhesion markers, though unchanged, significantly correlated with one another and with incretin hormones only after roflumilast. Conclusion: We demonstrate, for the first time in humans, increasing percentage of fat mass loss from roflumilast with increasing age in adults with prediabetes and overweight/obesity. We also demonstrate novel associations among roflumilast-induced changes in incretin hormones, inflammatory markers, peripheral insulin sensitivity, and adiposity. We conclude that roflumilast’s early effects on insulin sensitivity is indirect and likely mediated through roflumilast’s prioritization of lipid over glucose handling. Clinical trials registration: NCT01862029. Keywords: phosphodiesterase 4, obesity, diabetes, inflammation, incretins, aging

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.2147/dmso.s182953

Cites

65 of 65 references verified0 citation errors · 0 not checkable

Statistics

Figures

Figure 1 Spearman correlation demonstrating the significant associations among percentage changes in GLP-1 hormone and visceral adiposity in the leg skeletal muscle and in the abdomen, peripheral insulin sensitivity and leptin (A–F). Roflumilast induced alteration of insulin sensitivity is associated with changes in leptin (F) and in visceral adiposity (E). Notes: In this small study, the association of changes in GLP-1 AUC with changes in adiposity (A–C) suggests that roflumilast’s early effects on insulin sensitivity may be through reduction in adiposity and/or through incretin effect. Roflumilast-induced association between changes in soleus EMCL and L2-L3 visceral fat (D) highlights possible linkage between these two anatomically separate, visceral fat depot. Abbreviations: AUC, area under the curve; EMCL, extramyocellular lipid; GLP, glucagon-like peptide.
Figure 1 Spearman correlation demonstrating the significant associations among percentage changes in GLP-1 hormone and visceral adiposity in the leg skeletal muscle and in the abdomen, peripheral insulin sensitivity and leptin (A–F). Roflumilast induced alteration of insulin sensitivity is associated with changes in leptin (F) and in visceral adiposity (E). Notes: In this small study, the association of changes in GLP-1 AUC with changes in adiposity (A–C) suggests that roflumilast’s early effects on insulin sensitivity may be through reduction in adiposity and/or through incretin effect. Roflumilast-induced association between changes in soleus EMCL and L2-L3 visceral fat (D) highlights possible linkage between these two anatomically separate, visceral fat depot. Abbreviations: AUC, area under the curve; EMCL, extramyocellular lipid; GLP, glucagon-like peptide.CC BY-NC · PubMed Central
Figure 2 Spearman correlation demonstrating the age-associated effects of roflumilast on plasma free fatty acids and on fat mass loss. (A–D). The observed significant correlations (E and F) suggest that a majority of the changes in total body fat appears to stem from relative changes in fat mass in the leg and trunk regions.
Figure 2 Spearman correlation demonstrating the age-associated effects of roflumilast on plasma free fatty acids and on fat mass loss. (A–D). The observed significant correlations (E and F) suggest that a majority of the changes in total body fat appears to stem from relative changes in fat mass in the leg and trunk regions.CC BY-NC · PubMed Central
Figure 3 Roflumilast induced changes among incretin hormones, inflammatory, and adhesion markers with statistical significance fall within a constellation. Both interval changes in ICAM and E-selectin were associated (A). After roflumilast but not before roflumilast, ICAM and GLP-1 (B) and E-selectin and GIP (C) were significantly associated. After roflumilast but not before roflumilast, ICAM is also significantly associated with MCP and TNF-α (D and E). Abbreviations: AUC, area under the curve; GIP, glucose-dependent insulinotropic polypeptide or gastric inhibitory peptide; GLP, glucagon-like peptide; ICAM, intracellular adhesion molecule; MCP, monocyte chemoattractant protein; TNF, tumor necrosis factor.
Figure 3 Roflumilast induced changes among incretin hormones, inflammatory, and adhesion markers with statistical significance fall within a constellation. Both interval changes in ICAM and E-selectin were associated (A). After roflumilast but not before roflumilast, ICAM and GLP-1 (B) and E-selectin and GIP (C) were significantly associated. After roflumilast but not before roflumilast, ICAM is also significantly associated with MCP and TNF-α (D and E). Abbreviations: AUC, area under the curve; GIP, glucose-dependent insulinotropic polypeptide or gastric inhibitory peptide; GLP, glucagon-like peptide; ICAM, intracellular adhesion molecule; MCP, monocyte chemoattractant protein; TNF, tumor necrosis factor.CC BY-NC · PubMed Central
Figure 4 Spearman correlation demonstrating the significant associations among percentage changes in GIP hormone, adiponectin, and lumbar subcutaneous adiposity (A–D). Roflumilast induced change in lumbar subcutaneous adiposity is much more significantly associated with roflumilast-induced changes in the leptin and adiponectin ratio (D) than in interval changes in adiponectin ratio alone (C). Abbreviations: AUC, area under the curve; GIP, glucose-dependent insulinotropic polypeptide or gastric inhibitory peptide.
Figure 4 Spearman correlation demonstrating the significant associations among percentage changes in GIP hormone, adiponectin, and lumbar subcutaneous adiposity (A–D). Roflumilast induced change in lumbar subcutaneous adiposity is much more significantly associated with roflumilast-induced changes in the leptin and adiponectin ratio (D) than in interval changes in adiponectin ratio alone (C). Abbreviations: AUC, area under the curve; GIP, glucose-dependent insulinotropic polypeptide or gastric inhibitory peptide.CC BY-NC · PubMed Central
Figure 5 Working hypothesis for roflumilast’s age-associated beneficial changes in body composition. Abbreviation: cAMP, cyclic AMP.
Figure 5 Working hypothesis for roflumilast’s age-associated beneficial changes in body composition. Abbreviation: cAMP, cyclic AMP.CC BY-NC · PubMed Central

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Research works printed but not linked: 3

  1. [32]First MB Spitzer RL Gibbon M Williams JBW Structured Clinical Interview for DSM-IV Axis 1Disorders Washington, DC, USA American Psychiatric Press, Inc 1996
  2. [35]Institute of Medicine Dietary Reference Intakes: The Essential Guide to Nutrient Requirements Washington, DC The National Academies Press 2006
  3. [64]Burkewitz K Zhang Y Mair WB AMPK at the nexus of energetics and aging Cell Metab 2014 20 1 10 25 24726383 PMC4287273

Cited by

See all 21

Metadata

Authors
Muo, I. M., MacDonald, S. D., Madan, R., Park, S.-J., Gharib, A. M., Martinez, P. E., Walter, M. F., Yang, S. B., Rodante, J. A., Courville, A. B., Walter, P. J., Cai, H., Glicksman, M., Guerrieri, G. M., Ben-Dor, R. R., Ouwerkerk, R., Mao, S., & Chung, J. H.
Affiliations
National Institutes of Health (US)
Corresponding author
  • Muo, Ijeoma M
  • Chung, Jay H
Venue
Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy
Published
2019-05
Volume
Volume 12
Pages
743-759
ISSN
1178-7007 (ISSN-L)
OpenAlex
W2945096555
Cited by
21
References
65
Citations by year
2025: 6 · 2024: 4 · 2023: 4 · 2022: 3 · 2021: 2 · 2020: 1 · 2019: 1
FWCI
1.08
Type
journal article
Language
en
Open access
Locations
  • Diabetes Metabolic Syndrome and Obesity (publishedVersion, cc-by-nc)
  • Europe PMC (PubMed Central) (publishedVersion, cc-by-nc)
  • PubMed Central (publishedVersion, cc-by-nc)
  • PubMed (publishedVersion)
Funders
  • Medical College of Wisconsin
  • Endocrine Fellows Foundation
  • National Institutes of Health
  • National Institute of Mental Health
  • National Institute of Diabetes and Digestive and Kidney Diseases
  • National Institute of Child Health and Human Development
  • NIH Clinical Center
  • Eunice Kennedy Shriver National Institute of Child Health and Human Development
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Phosphodiesterase function and regulation
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Adipokines, Inflammation, and Metabolic Diseases
Keywords
prediabetes, obesity, insulin sensitivity, phosphodiesterase-4 inhibitors, fat loss, glucagon-like peptide-1, energy intake, free fatty acids, cholesterol, inflammation, mitochondrial function, incretins, weight loss, mixed meal tolerance test, hyperinsulinemic-euglycemic clamp, body composition

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.